Skip to main content
Top
Published in: Virology Journal 1/2013

Open Access 01-12-2013 | Research

Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

Authors: Abdel-Rahman N Zekri, Abeer A Bahnassy, Waleed S Mohamed, Hanaa M Alam EL-Din, Hend I Shousha, Naglaa Zayed, Dina H Eldahshan, Ashraf Omar Abdel-Aziz

Published in: Virology Journal | Issue 1/2013

Login to get access

Abstract

Background

Combined pegylated interferon-α and ribavirin therapy has sustained virological response (SVR) rates of 54% to 61%. Pretreatment predictors of SVR to interferon therapy have not been fully investigated yet. The current study assesses a group of chemokines that may predict treatment response in Egyptian patients with chronic HCV infection.

Patients and methods

CXCL5, CXCL9, CXCL11, CXCL12, CXCL 13, CXCL 16 chemokines and E-Cadherin were assayed in 57 chronic HCV patients’ sera using quantitative ELISA plate method. All studied patients were scheduled for combined pegylated interferon alpha and ribavirin therapy (32 patients received pegylated interferon α 2b, and 25 patients received pegylated interferon α 2a). Quantitative hepatitis C virus RNA was done by real time RT-PCR and HCV genotyping by INNOLIPAII.

Results

There was no significant difference (p > 0.05) in baseline HCV RNA levels between responders and non-responders to interferon. A statistically significant difference in CXCL13 (p = 0.017) and E-Cadherin levels (P = 0.041) was reported between responders and nonresponders at week 12. Significant correlations were found between changes in the CXCL13 levels and CXCL9, CXCL16, E-cadherin levels as well as between changes in E-cadherin levels and both CXCL16 and ALT levels that were maintained during follow up. Also, significant changes have been found in the serum levels of CXCL5, CXCL13, and CXCL16 with time (before pegylated interferon α 2 a and α 2 b therapy, and at weeks 12 and 24) with no significant difference in relation to interferon type and response to treatment.

Conclusion

Serum levels of CXCL13 and E-Cadherin could be used as surrogate markers to predict response of combined PEG IFN-α/RBV therapy, especially at week 12. However, an extended study including larger number of patients is needed for validation of these findings.

Clinical trial No

Appendix
Available only for authorised users
Literature
2.
go back to reference Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I: The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000,355(9207):887-891. 10.1016/S0140-6736(99)06527-7PubMedCrossRef Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I: The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000,355(9207):887-891. 10.1016/S0140-6736(99)06527-7PubMedCrossRef
4.
go back to reference Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL: Genetic epidemiology of hepatitis C virus throughtout Egypt. J Infect Dis 2000, 182: 698-707. 10.1086/315786PubMedCrossRef Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL: Genetic epidemiology of hepatitis C virus throughtout Egypt. J Infect Dis 2000, 182: 698-707. 10.1086/315786PubMedCrossRef
5.
go back to reference Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group: Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140: 346-355. 10.7326/0003-4819-140-5-200403020-00010PubMedCrossRef Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group: Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140: 346-355. 10.7326/0003-4819-140-5-200403020-00010PubMedCrossRef
6.
go back to reference Reddy KR, Messinger D, Popescu M, Hadziyannis SJ: Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in Sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat 2009,16(10):724-731. 10.1111/j.1365-2893.2009.01122.xPubMedCrossRef Reddy KR, Messinger D, Popescu M, Hadziyannis SJ: Peginterferon alfa-2a (40kDa) and ribavirin: comparable rates of sustained virological response in Sub-sets of older and younger HCV genotype 1 patients. J Viral Hepat 2009,16(10):724-731. 10.1111/j.1365-2893.2009.01122.xPubMedCrossRef
7.
go back to reference Gao B, Hong F, Radaeva S: Host factors and failure of interferon-a treatment in hepatitis C virus. Hepatology 2004, 39: 880-890. 10.1002/hep.20139PubMedCrossRef Gao B, Hong F, Radaeva S: Host factors and failure of interferon-a treatment in hepatitis C virus. Hepatology 2004, 39: 880-890. 10.1002/hep.20139PubMedCrossRef
8.
go back to reference Lee SS, Abdo AA: Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon? J Antimicrob Chemother 2003, 51: 487-491. 10.1093/jac/dkg135PubMedCrossRef Lee SS, Abdo AA: Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon? J Antimicrob Chemother 2003, 51: 487-491. 10.1093/jac/dkg135PubMedCrossRef
9.
go back to reference Kamal S: Improving outcome in patients with hepatitis C virus genotype 4. Am J Gastroenterology 2007, 102: 2582-2588. 10.1111/j.1572-0241.2007.01538.xCrossRef Kamal S: Improving outcome in patients with hepatitis C virus genotype 4. Am J Gastroenterology 2007, 102: 2582-2588. 10.1111/j.1572-0241.2007.01538.xCrossRef
10.
go back to reference Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F, Observational VHC4 Study Group: Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepatitis 2007, 14: 460-467. 10.1111/j.1365-2893.2006.00823.xCrossRef Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F, Observational VHC4 Study Group: Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepatitis 2007, 14: 460-467. 10.1111/j.1365-2893.2006.00823.xCrossRef
11.
go back to reference Zekri AR, Haleem HA, Esmat GE-D, Bahnassy AA, El-Din HMA, Hafez MM MM, Sharaby AF, Sharaf H, Zakaria MSE-D: Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. J Viral Hepatitis 2007, 14: 468-477. 10.1111/j.1365-2893.2006.00832.xCrossRef Zekri AR, Haleem HA, Esmat GE-D, Bahnassy AA, El-Din HMA, Hafez MM MM, Sharaby AF, Sharaf H, Zakaria MSE-D: Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. J Viral Hepatitis 2007, 14: 468-477. 10.1111/j.1365-2893.2006.00832.xCrossRef
12.
go back to reference El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK: Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009, 81: 1576-1583. 10.1002/jmv.21570PubMedCrossRef El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK: Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009, 81: 1576-1583. 10.1002/jmv.21570PubMedCrossRef
13.
go back to reference Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu-Shady MA: Cytokine profile in Egyptian HCV genotype-4 in relation to liver disease progression. World J Gastroenterol 2005,11(42):6624-6630.PubMedPubMedCentralCrossRef Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu-Shady MA: Cytokine profile in Egyptian HCV genotype-4 in relation to liver disease progression. World J Gastroenterol 2005,11(42):6624-6630.PubMedPubMedCentralCrossRef
14.
go back to reference Wald O, Weiss ID, Galun E, Peled A: Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. Cytokine 2007, 39: 50-62. 10.1016/j.cyto.2007.05.013PubMedCrossRef Wald O, Weiss ID, Galun E, Peled A: Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics. Cytokine 2007, 39: 50-62. 10.1016/j.cyto.2007.05.013PubMedCrossRef
15.
go back to reference Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C: Association of pretreatment serum interferon c inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy ingenotype 1 infected patients with chronic hepatitis C. Gut 2006, 55: 374-379. 10.1136/gut.2005.074062PubMedPubMedCentralCrossRef Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C: Association of pretreatment serum interferon c inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy ingenotype 1 infected patients with chronic hepatitis C. Gut 2006, 55: 374-379. 10.1136/gut.2005.074062PubMedPubMedCentralCrossRef
16.
go back to reference Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML: Evidence for an antagonistform of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011,121(1):308-317. 10.1172/JCI40594PubMedPubMedCentralCrossRef Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML: Evidence for an antagonistform of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011,121(1):308-317. 10.1172/JCI40594PubMedPubMedCentralCrossRef
17.
go back to reference Moura AS, Carmo RA, Teixeira AL, Teixeira MM, Rocha MO: Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin. Memorias do Instituto Oswaldo Cruz 2011,106(1):38-43. 10.1590/S0074-02762011000100006PubMedCrossRef Moura AS, Carmo RA, Teixeira AL, Teixeira MM, Rocha MO: Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin. Memorias do Instituto Oswaldo Cruz 2011,106(1):38-43. 10.1590/S0074-02762011000100006PubMedCrossRef
18.
go back to reference Zeremski M, Petrovic LM, Talal AH: The role of chemokines as inflammatory Mediators in Chronic Hepatitis C Virus Infection. J Viral Hepat 2007,14(10):675-687.PubMed Zeremski M, Petrovic LM, Talal AH: The role of chemokines as inflammatory Mediators in Chronic Hepatitis C Virus Infection. J Viral Hepat 2007,14(10):675-687.PubMed
19.
go back to reference Rot A, Von Andrian UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004, 22: 891-928. 10.1146/annurev.immunol.22.012703.104543PubMedCrossRef Rot A, Von Andrian UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004, 22: 891-928. 10.1146/annurev.immunol.22.012703.104543PubMedCrossRef
20.
go back to reference Wan L, Kung YJ, Lin YJ, Liao CC, Sheu JJ, Tsai Y, Lai HC, Peng CY, Tsai FJ: Th1 and Th2 cytokines are elevated in HCV-infected SVR(+) patients treated with interferon-a. Biochemical and Biophysical Research Communications 2009, 379: 855-860. 10.1016/j.bbrc.2008.12.114PubMedCrossRef Wan L, Kung YJ, Lin YJ, Liao CC, Sheu JJ, Tsai Y, Lai HC, Peng CY, Tsai FJ: Th1 and Th2 cytokines are elevated in HCV-infected SVR(+) patients treated with interferon-a. Biochemical and Biophysical Research Communications 2009, 379: 855-860. 10.1016/j.bbrc.2008.12.114PubMedCrossRef
21.
go back to reference Dou J, Wang J, Liu PB, Zhang XJ: Gene expression profiles on three kinds of genotype hepatitis C virus core protein in Huh-7 cell line with microarray analysis. Zhonghua Yu Fang Yi Xue Za Zhi 2006,40(1):38-41.PubMed Dou J, Wang J, Liu PB, Zhang XJ: Gene expression profiles on three kinds of genotype hepatitis C virus core protein in Huh-7 cell line with microarray analysis. Zhonghua Yu Fang Yi Xue Za Zhi 2006,40(1):38-41.PubMed
22.
go back to reference Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB: Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005, 106: 1175-1182. 10.1182/blood-2005-01-0126PubMedPubMedCentralCrossRef Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB: Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005, 106: 1175-1182. 10.1182/blood-2005-01-0126PubMedPubMedCentralCrossRef
23.
go back to reference Perney P, Turriere C, Portalès P, Rigole H, Psomas C, Blanc F, Clot J, Corbeau P: CXCR3 expression on peripheral CD4+ T cells as a predictive marker of response to treatment in chronic hepatitis C. Clin. Immunol 2009,132(1):55-62. 10.1016/j.clim.2009.03.521PubMedCrossRef Perney P, Turriere C, Portalès P, Rigole H, Psomas C, Blanc F, Clot J, Corbeau P: CXCR3 expression on peripheral CD4+ T cells as a predictive marker of response to treatment in chronic hepatitis C. Clin. Immunol 2009,132(1):55-62. 10.1016/j.clim.2009.03.521PubMedCrossRef
24.
go back to reference Cicinnati VR, Kang J, Sotiropoulos GC, Hilgard P, Frilling A, Broelsch CE, Gerken G, Beckebaum S: Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. Journal of General Virology 2008, 89: 1243-1253. 10.1099/vir.0.83517-0PubMedCrossRef Cicinnati VR, Kang J, Sotiropoulos GC, Hilgard P, Frilling A, Broelsch CE, Gerken G, Beckebaum S: Altered chemotactic response of myeloid and plasmacytoid dendritic cells from patients with chronic hepatitis C: role of alpha interferon. Journal of General Virology 2008, 89: 1243-1253. 10.1099/vir.0.83517-0PubMedCrossRef
25.
go back to reference Sansonno D, Tucci FA, Troiani L, Lauletta G, Montrone M, Conteduca V, Sansonno L, Dammacco F: Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vacuities. Blood 2008,112(5):1620-1627. 10.1182/blood-2008-02-137455PubMedCrossRef Sansonno D, Tucci FA, Troiani L, Lauletta G, Montrone M, Conteduca V, Sansonno L, Dammacco F: Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vacuities. Blood 2008,112(5):1620-1627. 10.1182/blood-2008-02-137455PubMedCrossRef
26.
go back to reference Balian A, Naveau S, Zou W, Durand-Gasselin I, Bouchet L, Foussat A, Galanaud P, Chaput JC, Emilie D: Pretreatment expression of the perforin gene by circulating CD8(+) T lymphocytes predicts biochemical response to interferon-alpha in patients with chronic hepatitis C. Eur. Cytokine Netw 2000, 11: 177-184.PubMed Balian A, Naveau S, Zou W, Durand-Gasselin I, Bouchet L, Foussat A, Galanaud P, Chaput JC, Emilie D: Pretreatment expression of the perforin gene by circulating CD8(+) T lymphocytes predicts biochemical response to interferon-alpha in patients with chronic hepatitis C. Eur. Cytokine Netw 2000, 11: 177-184.PubMed
27.
go back to reference Biron CA: Interferons alpha and beta as immune regulators—a new look. Immunity 2001, 14: 661-664. 10.1016/S1074-7613(01)00154-6PubMedCrossRef Biron CA: Interferons alpha and beta as immune regulators—a new look. Immunity 2001, 14: 661-664. 10.1016/S1074-7613(01)00154-6PubMedCrossRef
28.
go back to reference Hirohashi S, Kanai Y: Cell adhesion system and human cancer morphogenesis. Cancer Sci 2005, 94: 575-581.CrossRef Hirohashi S, Kanai Y: Cell adhesion system and human cancer morphogenesis. Cancer Sci 2005, 94: 575-581.CrossRef
29.
go back to reference Arora P, Kim E, Jung J, Jank KL: Hepatitis C virus core protein downregulates E- cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Letters 2008, 261: 244-252. 10.1016/j.canlet.2007.11.033PubMedCrossRef Arora P, Kim E, Jung J, Jank KL: Hepatitis C virus core protein downregulates E- cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Letters 2008, 261: 244-252. 10.1016/j.canlet.2007.11.033PubMedCrossRef
31.
go back to reference Zekri AR, Bahnassy AA, Alam El-Din HM, Salama HM: Consensus siRNA for inhibition of HCV genotype-4 replication. Virology J 2009, 6: 13. 10.1186/1743-422X-6-13CrossRef Zekri AR, Bahnassy AA, Alam El-Din HM, Salama HM: Consensus siRNA for inhibition of HCV genotype-4 replication. Virology J 2009, 6: 13. 10.1186/1743-422X-6-13CrossRef
32.
go back to reference Zekri AR, El-Din HM, Bahnassy AA, El-Shehabi AM, El-Leethy H, Omar A, Khaled HM: TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4. J Med Virol 2005,75(3):412-420. 10.1002/jmv.20293PubMedCrossRef Zekri AR, El-Din HM, Bahnassy AA, El-Shehabi AM, El-Leethy H, Omar A, Khaled HM: TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4. J Med Virol 2005,75(3):412-420. 10.1002/jmv.20293PubMedCrossRef
33.
go back to reference Knodell RG, Ishak KG, Black WC: Formulation and application of numerical scaring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1: 431-435. 10.1002/hep.1840010511PubMedCrossRef Knodell RG, Ishak KG, Black WC: Formulation and application of numerical scaring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1: 431-435. 10.1002/hep.1840010511PubMedCrossRef
34.
go back to reference Desmet VJ, Gerber M, Hoofnagle JH: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19: 1513-1520. 10.1002/hep.1840190629PubMedCrossRef Desmet VJ, Gerber M, Hoofnagle JH: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19: 1513-1520. 10.1002/hep.1840190629PubMedCrossRef
Metadata
Title
Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon
Authors
Abdel-Rahman N Zekri
Abeer A Bahnassy
Waleed S Mohamed
Hanaa M Alam EL-Din
Hend I Shousha
Naglaa Zayed
Dina H Eldahshan
Ashraf Omar Abdel-Aziz
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2013
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-10-218

Other articles of this Issue 1/2013

Virology Journal 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine